Table 2 Baseline clinical characteristics and in-hospital outcomes of the study patients according to hs-CRP value at hospital admission
|  | Hs-CRP > 2 mg/L (n = 1366) | Hs-CRP < 2 mg/L (n = 698) | P value |
|---|---|---|---|
Age (years) | 68 ± 12 | 65 ± 12 | < 0.0001 |
Male sex, n (%) | 980 (72%) | 536 (77%) | 0.01 |
Body mass index (kg/m2) | 27 ± 5 | 26 ± 4 | < 0.0001 |
Hypertension, n (%) | 920 (67%) | 416 (60%) | 0.0004 |
Diabetes mellitus, n (%) | 403 (29%) | 145 (21%) | < 0.0001 |
Smokers, n (%) | 474 (35%) | 216 (31%) | 0.0001 |
Dyslipidemia, n (%) | 680 (50%) | 350 (50%) | 0.90 |
STEMI, n (%) | 683 (50%) | 333 (48%) | 0.32 |
Prior MI, n, (%) | 337 (25%) | 198 (28%) | 0.07 |
Prior CABG, n (%) | 175 (13%) | 76 (11%) | 0.20 |
Prior PCI, n (%) | 308 (23%) | 210 (30%) | 0.0002 |
LVEF (%) | 49 ± 12 | 52 ± 11 | < 0.0001 |
Time-to-presentation (hours) | 12.9 ± 25.1 | 12.2 ± 27.5 | 0.56 |
CA/PCI in hospital, n (%) | 1260 (92%) | 671 (96%) | 0.0008 |
Laboratory values at hospital admission | |||
 hs-CRP (mg/L) | 7.37 (3.80–24.11) | 1.03 (0.67–1.45)- |  |
 Blood glucose (mg/dl) | 157 ± 68 | 141 ± 52 | < 0.0001 |
 HbA1c (%) | 6.1 ± 1.3 | 5.9 ± 1.1 | 0.001 |
 Serum creatinine (mg/dl) | 0.95 (0.8–1.2) | 0.92 (0.8–1.1) | 0.001 |
 eGFR (ml/min/1.73 m2) | 76 ± 27 | 82 ± 26 | < 0.0001 |
 Hemoglobin (g/dl) | 13 ± 2 | 14 ± 2 | < 0.0001 |
 hs-Tn I (ng/L) | 7485 ± 27,414 | 3468 ± 21,357 | 0.001 |
Medication before AMI | |||
 Statins, n (%) | 429 (32%) | 262 (38%) | 0.001 |
 ACEi/ARB, n (%) | 528 (39%) | 284 (41%) | 0.36 |
 Beta-blockers, n (%) | 498 (36%) | 235 (34%) | 0.21 |
 Aspirin, n (%) | 496 (36%) | 254 (36%) | 0.96 |
In-hospital complications | |||
 Death, n (%) | 30 (2.2%) | 10 (1.4%) | 0.23 |
 Cardiogenic shock, n (%) | 90 (7%) | 27 (4%) | 0.01 |
 Acute pulmonary edema, n (%) | 179 (13%) | 35 (5%) | < 0.0001 |
 Mechanical ventilation, n (%) | 58 (4%) | 20 (3%) | 0.12 |
 Atrial fibrillation, n (%) | 160 (12%) | 49 (7%) | < 0.0001 |
 VT/VF, n (%) | 101 (7%) | 67 (10%) | 0.08 |
 High-degree AV block, n (%) | 54 (4%) | 20 (3%) | 0.21 |
 Major bleeding, n (%) | 59 (4%) | 13 (2%) | 0.004 |
Medication at hospital discharge | |||
 Dual antiplatelet therapy, n (%) | 1201 (90%) | 623 (91%) | 0.64 |
 Statins, n (%) | 1214 (91%) | 640 (92%) | 0.30 |
 Beta-blockers, n (%) | 444 (83%) | 1138 (77%) | 0.002 |
 ACEi/ARB, n (%) | 839 (63%) | 418 (60%) | 0.27 |